Stimulation of Ebola virus production from persistent infection through activation of the Ras/mapk pathway

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 46, 2008, Pages 17982-17987

  Strong, James E ^a,b   Wong, Gary ^a   Jones, Shane E ^a   Grolla, Allen ^a   Theriault, Steven ^b,c   Kobinger, Gary P ^a   Feldmann, Heinz ^a,b,d  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 2ALPHA; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE; RAS PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EBOLA VIRUS; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; VIRUS IDENTIFICATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; CELL LINE, TRANSFORMED; CHIROPTERA; DOSE-RESPONSE RELATIONSHIP, DRUG; EBOLAVIRUS; ENZYME ACTIVATION; EUKARYOTIC INITIATION FACTOR-2; FEMALE; GREEN FLUORESCENT PROTEINS; HEMORRHAGIC FEVER, EBOLA; LIPOPOLYSACCHARIDES; LIVER; MACROPHAGES; MICE; MICE, INBRED BALB C; MITOGEN-ACTIVATED PROTEIN KINASES; NIH 3T3 CELLS; PHOSPHORYLATION; RAS PROTEINS; SPLEEN; TETRADECANOYLPHORBOL ACETATE;

ANIMALIA; EBOLA VIRUS; EUKARYOTA; MUS; PRIMATES;

EID: 56649108088     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0809698105     Document Type: Article

References (59)

1. Bausch DG, Geisbert TW (2007) Development of vaccines for Marburg hemorrhagic fever. Expert Rev Vaccines 6:57-74.
2. Paragas J, Geisbert TW (2006) Development of treatment strategies to combat Ebola and Marburg viruses. Expert Rev Anti Infect Ther 4:67-76.
3. Feldmann H, Jones SM, Schnittler HJ, Geisbert T (2005) Therapy and prophylaxis of Ebola virus infections. Curr Opin Investig Drugs 6:823-830.
4. Geisbert TW, Jahrling PB (2003) Towards a vaccine against Ebola virus. Expert Rev Vaccines 2:777-789.
5. Feldmann H, Jones S, Klenk HD, Schnittler HJ (2003) Ebola virus: From discovery to vaccine. Nat Rev Immunol 3:677-685.
6. Sullivan N, Yang ZY, Nabel GJ (2003) Ebola virus pathogenesis: Implications for vaccines and therapies. J Virol 77:9733-9737.
7. Swanepoel R, et al. (1996) Experimental inoculation of plants and animals with Ebola virus. Emerg Infect Dis 2:321-325.
8. Breman JG, et al. (1999) A search for Ebola virus in animals in the Democratic Republic of the Congo and Cameroon: Ecologic, virologic, and serologic surveys, 1979-1980. Ebola Virus Study Teams. J Infect Dis 179(Suppl 1):S139-S147.
9. Reiter P, et al. (1999) Field investigations of an outbreak of Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: Arthropod studies. J Infect Dis 179(Suppl 1):S148-S154.
10. Leirs H, et al. (1999) Search for the Ebola virus reservoir in Kikwit, Democratic Republic of the Congo: Reflections on a vertebrate collection. J Infect Dis 179(Suppl 1):S155-S163.
11. HCaPRW Group (1995) WHO-led collaborative study in Cote D'Ivoire to identify the natural host reservoir of the Ebola virus. Press release WHO/93 (http://www.who.int/archives/inf-pr-1995/pr95-93.html).
12. Morvan JM, et al. (1999) Identification of Ebola virus sequences present as RNA or DNA in organs of terrestrial small mammals of the Central African Republic. Microbes Infect 1:1193-1201.
13. Gunther S, Lenz O (2004) Lassa virus. Crit Rev Clin Lab Sci 41:339-390.
14. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J (1998) A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 178:651-661.
15. Bray M (2001) The role of the type I interferon response in the resistance of mice to filovirus infection. J Gen Virol 82:1365-1373.
16. Warfield KL, et al. (2004) Role of natural killer cells in innate protection against lethal Ebola virus infection. J Exp Med 200:169-179.
17. Warfield KL, et al. (2007) Development of a model for Marburg virus based on severe combined immunodeficiency mice. Virol J 4:108-121.
18. Connolly BM, et al. (1999) Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 179(Suppl 1):S203-S217.
19. Ebihara H, et al. (2006) Molecular determinants of Ebola virus virulence in mice. PLoS Pathog 2:0705-0711.
20. Leroy EM, et al. (2005) Fruit bats as reservoirs of Ebola virus. Nature 438:575-576.
21. Towner JS, et al. (2007) Marburg virus infection detected in a common African bat. PLoS ONE 2:1-5.
22. Swanepoel R, et al. (2007) Studies of reservoir hosts for Marburg virus. Emerg Infect Dis 13:1847-1851.
23. Ebihara H, et al. (2007) In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein. J Infect Dis 196(Suppl 2):S313-S322.
24. Tan CT, et al. (2002) Relapsed and late-onset Nipah encephalitis. Ann Neurol 51:703-708.
25. Ellenberg P, Linero FN, Scolaro LA (2007) Superinfection exclusion in BHK-21 cells persistently infected with Junin virus. J Gen Virol 88:2730-2739.
26. Meyer BJ, Schmaljohn CS (2000) Persistent hantavirus infections: characteristics and mechanisms. Trends Microbiol 8:61-67.
27. Rima BK, Duprex WP (2005) Molecular mechanisms of measles virus persistence. Virus Res 111:132-147.
28. Martinez-Sobrido L, Zuniga EI, Rosario D, Garcia-Sastre A, de la Torre JC (2006) Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol 80:9192-9199.
29. Rodriguez LL, et al. (1999) Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 179(Suppl 1):S170-S176.
30. Okada Y, et al. (1995) Viral activation from latency during retrodifferentiation of U937 cells exposed to phorbol ester followed by infection with human immunodeficiency virus type 1. Immunopharmacology 30:27-39.
31. Ford PW, et al. (2006) Raf/MEK/ERK signaling triggers reactivation of Kaposi's sarcoma-associated herpesvirus latency. J Gen Virol 87:1139-1144.
32. Smith RL, Pizer LI, Johnson EM, Jr, Wilcox CL (1992) Activation of second-messenger pathways reactivates latent herpes simplex virus in neuronal cultures. Virology 188:311-318.
33. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW (1998) The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus. EMBO J 17:3351-3362.
34. Mundschau LJ, Faller DV (1992) Oncogenic ras induces an inhibitor of double-stranded RNA-dependent eukaryotic initiation factor 2 alpha-kinase activation. J Biol Chem 267:23092-23098.
35. Farassati F, Yang AD, Lee PW (2001) Oncogenes in Ras signaling pathway dictate host cell permissiveness to herpes simplex virus 1. Nat Cell Biol 3:745-750.
36. Battcock SM, Collier TW, Zu D, Hirasawa K (2006) Negative regulation of the alpha interferon-induced antiviral response by the Ras/Raf/MEK pathway. J Virol 80:4422-4430.
37. Zhang JS, Feng WG, Li CL, Wang XY, Chang ZL (2000) NF-kappa B regulates the LPS-induced expression of interleukin 12 p40 in murine peritoneal macrophages: Roles of PKC, PKA, ERK, p38 MAPK, and proteasome. Cell Immunol 204:38-45.
38. Lucchi NW, Moore JM (2007) LPS induces secretion of chemokines by human syncytiotrophoblast cells in a MAPK-dependent manner. J Reprod Immunol 73:20-27.
39. Marquardt B, Frith D, Stabel S (1994) Signaling from TPA to MAP kinase requires protein kinase C, raf and MEK: Reconstitution of the signaling pathway in vitro. Oncogene 9:3213-3218.
40. Li C, et al. (2008) Both ERK and JNK pathways are required for PMA-induced MD-2 gene expression during HL-60 cell differentiation. Biol Cell 100(6):365-375.
41. Emeny JM, Morgan MJ (1979) Regulation of the interferon system: Evidence that Vero cells have a genetic defect in interferon production. J Gen Virol 43:247-252.
42. Desmyter J, Melnick JL, Rawls WE (1968) Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero). J Virol 2:955-961.
43. Mundschau LJ, Faller DV (1994) Endogenous inhibitors of the dsRNA-dependent eIF-2 alpha protein kinase PKR in normal and ras-transformed cells. Biochimie 76:792-800.
44. Thomis DC, Samuel CE (1995) Mechanism of interferon action: Characterization of the intermolecular autophosphorylation of PKR, the interferon-inducible, RNA-dependent protein kinase. J Virol 69:5195-5198.
45. Zhou Y, Chase BI, Whitmore M, Williams BR, Zhou A (2005) Double-stranded RNA-dependent protein kinase (PKR) is downregulated by phorbol ester. FEBS J 272:1568-1576.
46. Calain P, Monroe MC, Nichol ST (1999) Ebola virus defective interfering particles and persistent infection. Virology 262:114-128.
47. Gupta M, et al. (2004) Persistent infection with Ebola virus under conditions of partial immunity. J Virol 78:958-967.
48. Martini GA (1969) Marburg agent disease in man. Trans R Soc Trop Med Hyg 63:295-302.
49. Smith DH, et al. (1982) Marburg virus disease in Kenya. Lancet 319:816-820.
50. Emond RT, Evans B, Bowen ET, Lloyd G (1977) A case of Ebola virus infection. BMJ 2:541-544.
51. Bausch DG, et al. (2007) Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 196(Suppl 2):S142-S147.
52. Groseth A, Feldmann H, Strong JE (2007) The ecology of Ebola virus. Trends Microbiol 15:408-416.
53. Sadiq ST, et al. (2005) The effects of early syphilis on CD4 counts and HIV-1 RNA viral loads in blood and semen. Sex Transm Infect 81:380-385.
54. McCullers JA (2006) Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 19:571-582.
55. Slots J (2007) Herpesviral-bacterial synergy in the pathogenesis of human periodontitis. Curr Opin Infect Dis 20:278-283.
56. Williamson MM, Hooper PT, Selleck PW, Westbury HA, Slocombe RF (2000) Experimental Hendra virus infection in pregnant guinea pigs and fruit bats (Pteropus poliocephalus). J Comp Pathol 122:201-207.
57. Field H, et al. (2001) The natural history of Hendra and Nipah viruses. Microbes Infect 3:307-314.
58. Yadav VK, Medhamurthy R (2006) Dynamic changes in mitogen-activated protein kinase (MAPK) activities in the corpus luteum of the bonnet monkey (Macaca radiata) during development, induced luteolysis, and simulated early pregnancy: A role for p38 MAPK in the regulation of luteal function. Endocrinology 147:2018-2027.
59. Noda T, et al. (2002) Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol 76:4855-4865.